Motif Neurotech raises $18.75M oversubscribed Series A for psychiatric BCI — $30M+ total with non-dilutive from ARIA, DARPA, NIH
Summary
Motif Neurotech closed an oversubscribed $18.75M Series A from Arboretum Ventures, KdT Ventures, and Dolby Family Ventures, bringing total funding to $30M+ including non-dilutive funding from UK government (ARIA multimillion dollar award), DARPA, and NIH. The company achieved FDA IDE for the RESONATE depression trial just 4 years after founding — the fastest IDE approval for any BCI company. Also exploring same DOT device over different brain targets for bipolar disorder, Alzheimer's, and substance use disorder.
Why it matters
The combination of oversubscribed VC Series A plus non-dilutive government funding from three countries (US-DARPA/NIH + UK-ARIA) makes Motif the most diversely funded early-stage psychiatric BCI company ever. The bipolar, Alzheimer's, and SUD expansion plans mean the DOT device — if RESONATE succeeds — immediately has a four-indication pipeline requiring no new hardware development.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial